This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen. (Cepacol Teen)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: August 4, 2008
Last updated: March 3, 2009
Last verified: March 2009
To prove the safety, in normal conditions, of the Cepacol Teen, a formulation to odontological usage.

Condition Intervention Phase
Hygiene Drug: Cetylpyridinium chloride Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single Site Study, Phase III, for Safety Dermatological Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Teen.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Patients will be evaluated according to the adverse reactions and the intensity of them. [ Time Frame: 21 days ]

Enrollment: 31
Study Start Date: July 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cetylpyridinium chloride during 21 consecutive days.
Drug: Cetylpyridinium chloride
Cetylpyridinium chloride during 21 consecutive days.


Ages Eligible for Study:   10 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Integral buccal mucous (without oral pathologies);
  • Normal odontological exams;

Exclusion Criteria:

  • Lactation or gestational risk or gestation;
  • Use of Antiinflammatory or immunosuppression drugs 15 days before the study;
  • Being in odontological treatment;
  • Pathological or mucous disease which can interfere or active gynaecological disease which may interfere wtih study results;
  • Personal history of allergic disease in the area to be treated;
  • Allergic or atopic history;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00729599

São Paulo, Brazil
Sponsors and Collaborators
Study Director: Jaderson Lima, MD Sanofi-aventis administrative office Brazil
  More Information

Responsible Party: Medical Affairs Study Director, Sanofi-aventis Identifier: NCT00729599     History of Changes
Other Study ID Numbers: CPYRY_L_04020
Study First Received: August 4, 2008
Last Updated: March 3, 2009

Additional relevant MeSH terms:
Dermatologic Agents
Anti-Infective Agents, Local
Anti-Infective Agents processed this record on September 21, 2017